, Volume 17, Issue 3, pp 277–283 | Cite as

GH/IGF1 axis disturbances in the fibromyalgia syndrome: is there a rationale for GH treatment?



Fibromyalgia Syndrome (FMS) is a frequent idiopathic condition in which patients experience intense pain in specific tender points, profound fatigue and sleep disturbances. Although pain had not account so far in growth hormone deficiency syndrome (GHD) description, symptoms of FMS are very similar; and there is strong evidence of decreased GH secretion at least in a subset of FMS patients. Is there an overlap of the two diseases? A systematic Medline/Embase search for preliminary proof-of-concept trials, but also larger placebo-controlled studies, have shown that GH replacement in low-IGF1 patients can significantly improve some symptoms of FMS and quality of life, suggesting a direct causal effect of GH deficiency. Despite the use of relatively high doses of GH in these patients, treatment seems to be well tolerated. Several mechanisms of action for GH in FMS relief have been suggested, including both central modulation of pain and peripheral musculo-tendinous effects, as already described in classic GHD.


Adult growth hormone deficiency Fibromyalgia Growth hormone GH resistance IGF1 Quality of life 


Conflict of interest

Receiving fees for lecturing and advisory boards from Ipsen and Merck (GC), and Novartis and Pfizer (FFC).


  1. 1.
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, Mccain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33:160–172PubMedCrossRefGoogle Scholar
  2. 2.
    Wolfe F (2010) New American College of Rheumatology criteria for fibromyalgia: a twenty-year journey. Arthritis Care Res 62(5):583–584CrossRefGoogle Scholar
  3. 3.
    Martinez-Lavin M (2001) Overlap of fibromyalgia with other medical conditions. Curr Pain Headache Rep 5:347–350PubMedCrossRefGoogle Scholar
  4. 4.
    de Alegre MC, Sellas FA (2008) Fibromyalgia: feeling and pain. Med Clin (Barc) 131(13):503–504CrossRefGoogle Scholar
  5. 5.
    de Alegre MC, Alejandra-Pereda C, Betina-Nishishinya M, Rivera J (2005) Systematic review of pharmacologic treatment in fibromyalgia. Med Clin (Barc) 125(20):784–787CrossRefGoogle Scholar
  6. 6.
    Moldofsky H, Inhaber NH, Guinta DR, Alvarez-Horine SB (2010) Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 37(10):2156–2166PubMedCrossRefGoogle Scholar
  7. 7.
    Owen RT (2008) Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today 44(9):653–660PubMedCrossRefGoogle Scholar
  8. 8.
    Carmona L, Ballina J, Gabriel R, Laffon A (2001) The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 60:1040–1045PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Mäkelä M, Heliövaara M (1991) Prevalence of primary fibromyalgia in the Finnish population. BMJ 303(6796):216–219PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Mease P (2005) Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 75:6–21PubMedGoogle Scholar
  11. 11.
    Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ (2003) Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 30:1318–1325PubMedGoogle Scholar
  12. 12.
    Lamotte M, Maugars Y, Le Lay K, Taïeb C (2010) Health economic evaluation of outpatient management of fibromyalgia patients and the costs avoided by diagnosing fibromyalgia in France. Clin Exp Rheumatol 28(6 Suppl 63):S64–S70PubMedGoogle Scholar
  13. 13.
    Thomas E, Ginies P, Blotman F (1999) Fibromyalgia as a national issue: the French example. Baillieres Best Pract Res Clin Rheumatol 13:525–529PubMedCrossRefGoogle Scholar
  14. 14.
    Department of Health (2006) The musculoskeletal services framework. Department of Health, LondonGoogle Scholar
  15. 15.
    Rivera J, Rejas J, Esteve-Vives J, Vallejo MA (2009) Resource utilisation and health care costs in patients diagnosed with fibromyalgia in Spain. Clin Exp Rheumatol 27(5 Suppl 56):S39–S45PubMedGoogle Scholar
  16. 16.
    Staud R, Robinson ME, Price DD (2007) Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J Pain 8:893–901PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK (2007) Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 27:10000–10006PubMedCrossRefGoogle Scholar
  18. 18.
    Emad Y, Ragab Y, Zeinhom F, El-Khouly G, Abou-Zeid A, Rasker JJ (2008) Hippocampus dysfunction may explain symptoms of fibromyalgia syndrome. A study with single-voxel magnetic resonance spectroscopy. J Rheumatol 35:1371–1377PubMedGoogle Scholar
  19. 19.
    Bennett RM (1989) Beyond fibromyalgia: ideas on etiology and treatment. J Rheumatol 19:185–191Google Scholar
  20. 20.
    Buskila D, Sarzi-Puttini P (2008) Fibromyalgia and autoimmune diseases: the pain behind autoimmunity. Isr Med Assoc J 10:77–78PubMedGoogle Scholar
  21. 21.
    Bazzichi L, Rossi A, Giuliano T, De Feo F, Giacomelli C, Consensi A, Ciapparelli A, Consoli G, Dell’osso L, Bombardieri S (2007) Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol 26(12):2115–2120PubMedCrossRefGoogle Scholar
  22. 22.
    Tanriverdi F, Karaca Z, Unluhizarci K, Kelestimur F et al (2007) The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress 10:13–25PubMedCrossRefGoogle Scholar
  23. 23.
    Izquierdo-Alvarez S, Bocos-Terraz JP, Bancalero-Flores JL (2008) Is there an association between fibromyalgia and below-normal levels of urinary cortisol? BMC Res Notes 1:134PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Giesecke T, Williams DA, Harris R, Cupps TR, Tian X, Tian TX, Gracely RH, Clauw DJ (2003) Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 48(10):2916–2922PubMedCrossRefGoogle Scholar
  25. 25.
    Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW, Hurley D (1998) The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 83(1):107–116PubMedGoogle Scholar
  26. 26.
    Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM (1997) Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 24:1384–1389PubMedGoogle Scholar
  27. 27.
    Cuatrecasas G, Gonzalez MJ, Alegre C, Sesmilo G, Fernandez-Solà J, Casanueva FF, Garcia-Fructuoso F, Poca-Dias V, Izquierdo JP, Puig-Domingo M (2010) High prevalence of growth hormone deficiency in severe fibromyalgia syndromes. J Clin Endocrinol Metab 95(9):4331–4337PubMedCrossRefGoogle Scholar
  28. 28.
    Leal-Cerro A, Povedano J, Astorga R, Gonzalez M, Silva H, Garcia- Pesquera F, Casanueva FF, Dieguez C (1999) The growth hormone (GH)- releasing hormone-GH-insulin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab 84:3378–3381PubMedGoogle Scholar
  29. 29.
    Denko CW, Malemud CJ (2005) Serum growth hormone and insulin but not insulin-like growth factor-1 levels are elevated in patients with fibromyalgia syndrome. Rheumatol Int 25:146–151PubMedCrossRefGoogle Scholar
  30. 30.
    Yuen KC, Bennett RM, Hryciw CA, Cook MB, Rhoads SA, Cook DM (2007) Is further evaluation for growth hormone (GH) deficiency necessary in fibromyalgia patients with low serum insulin-like growth factor (IGF)-I levels? Growth Horm IGF Res 17:82–88PubMedCrossRefGoogle Scholar
  31. 31.
    Griep EN, Boersma JW, de Kloet ER (1994) Pituitary release of growth hormone and prolactin in the primary fibromyalgia syndrome. J Rheumatol 21:2125–2130PubMedGoogle Scholar
  32. 32.
    Dinser R, Halama T, Hoffmann A (2000) Stringent endocrinological testing reveals subnormal growth hormone secretion in some patients with fibromyalgia syndrome but rarely severe growth hormone deficiency. J Rheumatol 27:2482–2488PubMedGoogle Scholar
  33. 33.
    Paul-Savoie E, Marchand S, Morin M, Bourgault P, Brissette N, Rattanavong V, Cloutier C, Bissonnette A, Potvin S (2012) Is the deficit in pain inhibition in fibromyalgia influenced by sleep impairments? Open Rheumatol J. 6:296–302PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Paiva ES, Deodhar A, Jones KD, Bennett R (2002) Impaired growth hormone secretion in fibromyalgia patients: evidence for augmented hypothalamic somatostatin tone. Arthritis Rheum 46:1344–1350PubMedCrossRefGoogle Scholar
  35. 35.
    Ferraccioli G, Guerra P, Rizzi V, Baraldo M, Salaffi F, Furlanut M, Bartoli E (1994) Somatomedin C (insulin-like growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia. J Rheumatol 21:1332–1334PubMedGoogle Scholar
  36. 36.
    Gianotti L, Broglio F, Aimaretti G, Arvat E, Colombo S, Di Summa M, Gallioli G, Pittoni G, Sardo E, Stella M, Zanello M, Miola C, Ghigo E (1998) Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions. J Endocrinol Invest 21(2):115–121PubMedCrossRefGoogle Scholar
  37. 37.
    Bennett RM, Clark SC, Walczyk J (1998) A randomized, double-blind, placebo- controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 104:227–231PubMedCrossRefGoogle Scholar
  38. 38.
    Cuatrecasas G, Riudavets C, Guell MA, Nadal A (2007) Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study. BMC Musculoskelet Disord 8:119PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Cuatrecasas G, Alegre C, Fernandez-Solà J, Gonzalez MJ, Garcia-Fructuoso F, Poca-Dias V, Nadal A, Cuatrecasas G, Navarro F, Mera A, Lage M, Peinó R, Casanueva F, Liñan C, Sesmilo G, Coves MJ, Izquierdo JP, Alvarez I, Granados E, Puig-Domingo M (2012) Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. Pain 153(7):1382–1389PubMedCrossRefGoogle Scholar
  40. 40.
    Yanmaz MN, Mert M, Korkmaz M (2012) The prevalence of diabetes mellitus in a group of fibromyalgia patients. Rheumatol Int 32(4):871–874PubMedCrossRefGoogle Scholar
  41. 41.
    Lathe R (2001) Hormones and the hippocampus. J Endocrinol 169:205–231PubMedCrossRefGoogle Scholar
  42. 42.
    Sverrisdottir YB, Elam M, Caidahl K, Soderling AS, Herlitz H, Johannsson G (2003) The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults. J Hypertens 21:1905–1914PubMedCrossRefGoogle Scholar
  43. 43.
    Chrousos GP, Kino T (2007) Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10:213–219PubMedCrossRefGoogle Scholar
  44. 44.
    Przewlocki R, Przewlocka B (2005) Opioids in neuropathic pain. Curr Pharm Des 11:3013–3025PubMedCrossRefGoogle Scholar
  45. 45.
    Cota D, Steiner MA, Marsicano G, Cervino C, Herman JP, Grübler Y, Stalla J, Pasquali R, Lutz B, Stalla GK, Pagotto U (2007) Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic- pituitary-adrenal axis function. Endocrinology 148:1574–1581PubMedCrossRefGoogle Scholar
  46. 46.
    Aberg ND, Johansson UE, Aberg MA, Hellstrom NA, Lind J, Bull C, Isgaard J, Anderson MF, Oscarsson J, Eriksson PS (2007) Peripheral infusion of insulin-like growth factor-I increases the number of newborn oligodendrocytes in the cerebral cortex of adult hypophysectomized rats. Endocrinology 148:3765–3772PubMedCrossRefGoogle Scholar
  47. 47.
    Chesik D, De Keyser J, Wilczak N (2008) Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J Mol Neurosci 35:81–90PubMedCrossRefGoogle Scholar
  48. 48.
    Isgaard J, Aberg D, Nilsson M (2007) Protective and regenerative effects of the GH/IGF-I axis on the brain. Minerva Endocrinol 32:103–113PubMedGoogle Scholar
  49. 49.
    Webb SM, de Andrés-Aguayo I, Rojas-García R, Ortega E, Gallardo E, Mestrón A, Serrano-Munuera C, Casamitjana R, Illa I (2003) Neuromuscular dysfunction in adult growth hormone deficiency. Clin Endocrinol (Oxf) 59:450–458CrossRefGoogle Scholar
  50. 50.
    Staud R (2006) Are tender point injections beneficial: the role of tonic nociception in fibromyalgia. Curr Pharm Des 12:23–27PubMedCrossRefGoogle Scholar
  51. 51.
    McKoy G, Ashley W, Mander J, Yang SY, Williams N, Russell B, Goldspink G (1999) Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiol 516:583–592PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    LeRoith D, Roberts CT Jr (1991) Insulin-like growth factor I (IGF-I): a molecular basis for endocrine versus local action? Mol Cell Endocrinol 77:C57–C61PubMedCrossRefGoogle Scholar
  53. 53.
    Stewart CE, Rotwein P (1996) Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts. J Biol Chem 271:11330–11338PubMedCrossRefGoogle Scholar
  54. 54.
    Guneli E, Kazikdas KC, Kolatan E (2007) Ghrelin may attenuate proinflammatory cytokine-mediated neuropathic pain. Med Hypotheses 69(2):356–360PubMedCrossRefGoogle Scholar
  55. 55.
    Commentary: The basis for medical therapy of fibromialgia with growth hormone. Malemud C. Pain 2012; 1342–1343Google Scholar
  56. 56.
    McCall-Hosenfeld JS, Goldenberg DL, Hurwitz S, Adler GK (2003) Growth hormone and insulin-like growth factor-1 concentrations in women with fibromyalgia. J Rheumatol 30(4):809–814PubMedGoogle Scholar
  57. 57.
    Jones KD, Deodhar AA, Burckhardt CS, Perrin NA, Hanson GC, Bennett RM (2007) A combination of 6 months of treatment with pyridostigmine and triweekly exercise fails to improve insulin-like growth factor-I levels in fibromyalgia, despite improvement in the acute growth hormone response to exercise. J Rheumatol 34(5):1103-1111PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Endocrinology DepartmentCPEN S.L, CM Teknon and Clinica Sagrada FamiliaBarcelonaSpain
  2. 2.Rheumatology DepartmentInstitut Universitari DexeusBarcelonaSpain
  3. 3.Department of MedicineComplejo Hospitalario Universitario de Santiago (CHUS), CIBER de Fisiopatologia Obesidad y Nutricion, Instituto Salud Carlos IIISantiago de CompostelaSpain

Personalised recommendations